Systemic sclerosis with associated interstitial lung disease: management considerations and future directions

Area of Science:

• Rheumatology
• Pulmonology
• Immunology

Background:

• Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune disorder characterized by vasculopathy, inflammation, and fibrosis.
• Interstitial lung disease (ILD) is a common and often fatal complication of SSc, carrying substantial economic implications.
• Current treatment for SSc-ILD primarily involves immunosuppressive agents.

Purpose of the Study:

• To review the current treatment landscape for SSc-ILD.
• To discuss the impact of emerging therapies, such as nintedanib, on managing SSc-ILD.
• To highlight the need for codified treatment guidelines and risk-stratification strategies.

Main Methods:

• Literature review of SSc-ILD epidemiology, economic burden, and treatment options.
• Analysis of the role of immunosuppressive and antifibrotic therapies.
• Discussion of emerging treatment guidelines and risk-stratification approaches.

Main Results:

• The treatment paradigm for SSc-ILD is evolving, with the 2019 FDA approval of nintedanib marking a significant advancement.
• A lack of standardized treatment guidelines complicates patient care and healthcare system burden.
• Future management may involve combination therapies and enhanced risk-stratification.

Conclusions:

• Nintedanib represents a new therapeutic option for SSc-ILD, expanding treatment possibilities beyond traditional immunosuppression.
• Developing clear treatment guidelines and implementing risk-stratification are crucial for optimizing patient outcomes and reducing the healthcare burden of SSc-ILD.
• A combined approach of immunosuppressive and antifibrotic therapies may be necessary to effectively reduce lung volume loss in SSc-ILD patients.